XML 70 R60.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Collaboration and License Agreements - Contract Liabilities - Additional Information (Details) - USD ($) $ in Thousands | 12 Months Ended |  |  |
--- | --- | --- | --- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Mar. 31, 2023 | Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 94,063 | $ 212,315 |  | $ 301,326
AbbVie Ireland Unlimited Company | CD71 Agreement |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue |  |  | $ 4,000 |
Amgen Inc | EGFR Products |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 9,700 |  |  |
Deferred Revenue Recognition Maturity Year | 2025 |  |  |
Astellas Pharma Inc. |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 17,400 |  |  |
Deferred Revenue Recognition Maturity Year | 2026 |  |  |
Bristol Myers Squibb |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 41,900 |  |  |
Deferred Revenue Recognition Maturity Year | 2025 |  |  |
ModernaTX, Inc |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 9,300 |  |  |
Deferred Revenue Recognition Maturity Year One | 2026 |  |  |
Deferred Revenue Recognition Maturity Year Two | 2027 |  |  |
Regeneron Pharmaceuticals, Inc |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Deferred revenue | $ 15,600 |  |  |
Deferred Revenue Recognition Maturity Year | 2026 |  |  |

X
- Definition Deferred revenue recognition maturity year. + References No definition available. + Details
Name: | ctmx_DeferredRevenueRecognitionMaturityYear
Namespace Prefix: | ctmx_
Data Type: | dtr-types:gYearListItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred revenue recognition maturity year one. + References No definition available. + Details
Name: | ctmx_DeferredRevenueRecognitionMaturityYearOne
Namespace Prefix: | ctmx_
Data Type: | dtr-types:gYearListItemType
Balance Type: | na
Period Type: | duration

X
- Definition Deferred revenue recognition maturity year two. + References No definition available. + Details
Name: | ctmx_DeferredRevenueRecognitionMaturityYearTwo
Namespace Prefix: | ctmx_
Data Type: | dtr-types:gYearListItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ctmx_EGFRProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_ModernatxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |